Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Tamas A. Gonda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0093-3738; OpenAlex author ID A5066665388. Sources: ClinicalTrials.gov.

Their work

Papers
21 (first author 3, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
94
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 3 papers, 1 trial · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 21

  1. Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2026.0372↗
  2. Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag091↗
  3. Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2025.3377↗
  4. Identification of patients at risk for pancreatic cancer in a 3-year timeframe based on machine learning algorithms. Last author DOI 10.1038/s41598-025-89607-8↗
  5. Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae200↗
  6. Cyst-X: AI-Powered Pancreatic Cancer Risk Prediction from Multicenter MRI in Centralized and Federated Learning Co-author DOI 10.21203/rs.3.rs-7236860/v1↗
  7. Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/curroncol32110638↗
  8. Epigenetic therapeutic strategies in pancreatic cancer. Last author DOI 10.1016/bs.ircmb.2023.10.002↗
  9. Somatic Mutational Analysis in Endoscopic Ultrasound-Guided Biopsy of Pancreatic Adenocarcinoma: Assessing Yield and Impact. Last author DOI 10.14309/ajg.0000000000002786↗
  10. Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Co-author DOI 10.1038/s41467-023-36296-4↗
  11. Author Correction: Single-cell RNA sequencing reveals the effects of chemotherapy on human pancreatic adenocarcinoma and its tumor microenvironment. Co-author DOI 10.1038/s41467-023-39680-2↗
  12. A Blueprint for a Comprehensive, Multidisciplinary Pancreatic Cancer Screening Program Last author DOI 10.14309/ajg.0000000000002534↗
  13. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  14. Missing links - epigenetic regulators of the pancreatic cancer-associated inflammation. First author DOI 10.1042/cs20210181↗
  15. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  16. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Co-author DOI 10.1136/gutjnl-2019-319912↗
  17. A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Canc… Co-author DOI 10.1158/0008-5472.can-20-0285↗
  18. ACR Appropriateness Criteria® Staging of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jacr.2017.08.050↗
  19. Early detection of pancreatic cancer. First author DOI 10.6092/1590-8577/729↗
  20. Early detection and screening of pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, … Co-author PMID 21386626↗
  21. Screening and detection of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. Co-author PMID 21737887↗

Trials 1

  1. EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC) Principal investigator NCT05723107↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Diane M. Simeone · 6 shared papers, 2021–2025 · strength 1.03
  2. Paul E. Oberstein · 5 shared papers, 2023–2026 · strength 0.96
  3. Gulam Abbas Manji · 3 shared papers, 2020–2026 · strength 0.64
  4. Gregor Werba · 3 shared papers, 2021–2023 · strength 0.55
  5. Matthew Fasullo · 2 shared papers, 2023–2024 · strength 0.43
  6. Ruth Aroon White · 2 shared papers, 2021–2026 · strength 0.37
  7. Arturo Orlacchio · 1 shared paper, 2024 · strength 0.36
  8. Fay Kastrinos · 2 shared papers, 2021–2025 · strength 0.34
  9. Jessica N. Everett · 2 shared papers, 2021–2023 · strength 0.30
  10. Shenin A. Sanoba · 1 shared paper, 2026 · strength 0.29
  11. Morgan E. Grams · 1 shared paper, 2026 · strength 0.29
  12. Lucas A. Mavromatis · 1 shared paper, 2026 · strength 0.29
  13. Michael D. Kluger · 1 shared paper, 2026 · strength 0.29
  14. Anirban Maitra · 1 shared paper, 2026 · strength 0.29
  15. Yvonne M. Saenger · 1 shared paper, 2025 · strength 0.28
  16. Karie D. Runcie · 1 shared paper, 2025 · strength 0.28
  17. Aristotelis Tsirigos · 2 shared papers, 2023 · strength 0.27
  18. Grace Oh · 2 shared papers, 2023 · strength 0.27
  19. Despoina Kalfakakou · 2 shared papers, 2023 · strength 0.27
  20. Mara H. Sherman · 2 shared papers, 2023 · strength 0.27
  21. Susan Elaine Bates · 1 shared paper, 2026 · strength 0.26
  22. Naomi Yamamoto · 1 shared paper, 2026 · strength 0.26
  23. Jacob K.R. Jamison · 1 shared paper, 2026 · strength 0.26
  24. Sita Kugel · 1 shared paper, 2026 · strength 0.26
  25. Rachael Ann Safyan · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.